Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement

M Ozdemirli1, J C Fanburg-Smith, D P Hartmann

  • 1Department of Pathology, Georgetown University Medical Center, 3900 Reservoir Road N.W., Washington, DC 20007, USA.

Insights

Distinguishing Ewing's sarcoma (ES) from precursor B-lymphoblastic lymphoma is crucial. This study highlights key immunophenotypic markers and gene rearrangement studies, including CD79a, CD43, TdT, and polymerase chain reaction (PCR), to avoid misdiagnosis in small round cell tumors.

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Background:

  • Small round cell tumors, particularly Ewing's sarcoma (ES) and lymphoblastic lymphoma, present diagnostic challenges.
  • Accurate differentiation is critical for appropriate patient treatment and prognosis.

Observation:

  • A case initially diagnosed as ES was reclassified as precursor B-lymphoblastic lymphoma based on positivity for CD79a, CD43, TdT, and immunoglobulin heavy chain gene rearrangement (IgH-R) via polymerase chain reaction (PCR).
  • Extensive investigation of 33 ES cases revealed consistent negativity for lymphoid markers (LCA, CD3, CD20, CD43, CD79a, TdT) and gene rearrangements (IgH-R, Tgamma-R).

Findings:

  • Ewing's sarcoma (ES) is characterized by negativity for lymphoid markers and gene rearrangements.
  • Precursor B-lymphoblastic lymphoma can exhibit varied immunophenotypic profiles, sometimes mimicking ES.
  • Immunohistochemistry (CD79a, CD43, TdT) and PCR for IgH-R and Tgamma-R are essential for differential diagnosis.

Implications:

  • Misdiagnosis between ES and lymphoblastic lymphoma can be avoided by comprehensive immunophenotypic and molecular analysis.
  • Standard diagnostic criteria for ES should include negativity for lymphoid markers and gene rearrangements.
  • Further evaluation of leukocyte antigens and gene rearrangement studies is recommended for challenging small round cell tumor cases.

Related Concept Videos